KLH in Clinical Trials

Clinical trials involving KLH. Details such as study status, design and investigators are available by link to outside sites.

Clinical trial links are intended for informational purposes only, and are not solicitations for any study nor provided for the purposes of giving medical advice. See Terms of Use for this site.

(in order by date)

Entries in KLH-Globo H (10)

Tuesday
May062014

NCT02132988

Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer

An Open Labeled Phase II Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: Ovarian Cancer
Sponsor: Mackay Memorial Hospital
Collaborator: OBI Pharma, Inc.
Phase II 

Thursday
Jan192012

NCT01516307

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
Sponsors: OBI Pharma, Inc.
Phase II

Thursday
May052011

NCT01349647

Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid

Conditions: Lung Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase: n/a 

Monday
Nov222010

NCT01248273

Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Conditions: Fallopian Tubes, Ovarian Cancer, Peritoneal Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase I

Thursday
Mar052009

NCT00857545

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Gynecologic Oncology Group, National Cancer Institute (NCI)
Phase II

Friday
Jun062008

NCT00693342

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Gynecologic Oncology Group, National Cancer Institute (NCI)
Phase III

Monday
May132002

NCT00036933

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center 
Phase II

Thursday
Feb142002

NCT00030823

Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

Conditions: Breast Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase I

Sunday
May062001

NCT00016120

Vaccine Therapy Plus Biological Therapy in Treating Patients With Relapsed Prostate Cancer

Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase II

Sunday
May062001

NCT00016146

Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer

Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase I